Pioneering precision radiopharmaceutical cancer therapies
RayzeBio (rayzebio.com) scores 76 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 52nd percentile of 19543 Healthcare brands.
RayzeBio is a biopharmaceutical company focused on developing precision radiopharmaceutical therapies (RPTs) for cancer treatment, with a particular emphasis on actinium-225-based alpha-emitting therapies. Its pipeline includes potentially first-in-class and best-in-class drug programs targeting various cancers. RayzeBio operates as part of Bristol Myers Squibb and serves oncologists, cancer patients, and the broader biopharmaceutical research community pursuing advanced radiopharmaceutical treatment options.
| Brand Name | RayzeBio |
|---|---|
| Domain | rayzebio.com |
| Industry | Healthcare |
| Parent Company / Owner | Bristol Myers Squibb |
| Main Competitors | Novartis (75/100), Fusion Pharmaceuticals (76/100), Telix Pharmaceuticals (75/100), POINT Biopharma (70/100), Actinium Pharmaceuticals (70/100), Lantheus Holdings (80/100), Orano Med (70/100), Perspective Therapeutics (68/100) |
Moz Domain Authority 34/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
Ranked #1,586,892 on the Tranco list of most-visited sites - modest traffic makes the brand easy for AI models to overlook.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "What We Do We are focused on creating precision radiopharmaceutical therapies (RPTs) that transform people’s lives. With an innovation-leading position in actinium-based RPTs and a…" (No meta description. OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: 1 JSON-LD block(s), Organization schema, Breadcrumb/Website schema, og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: robots.txt present, no AI bot restrictions - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Cloudflare, WordPress, Ghost.
Social footprint: verified profiles on LinkedIn, Facebook, Instagram, GitHub; no detected presence on X (Twitter), YouTube - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is RayzeBio?", Claude could identify the brand as of October 2026. RayzeBio is a clinical-stage radiopharmaceutical company that develops targeted radioligand therapeutics for treating solid tumors, using actinium-225 and other isotopes to deliver radiation directly to cancer cells. Best known for Being acquired by Bristol Myers Squibb in early 2024 for roughly $4.1 billion to bolster BMS's radiopharmaceutical oncology pipeline.
When asked "Best brands similar to RayzeBio?", Claude would recommend RayzeBio as of October 2026. It's a notable name in the growing radioligand therapy space for cancer treatment, especially given its high-profile acquisition by a major pharma company.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
RayzeBio's main competitors in Healthcare: Novartis (75/100), Fusion Pharmaceuticals (76/100), Telix Pharmaceuticals (75/100), POINT Biopharma (70/100), Actinium Pharmaceuticals (70/100).
Sources: Brand Analyzer scan
RayzeBio has low AI-search visibility, scoring 23/100 on Brand Analyzer's AI visibility composite (visibility 0, trust 39, recommendation 45). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: RayzeBio official site
RayzeBio scores 45/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: RayzeBio official site
RayzeBio offers a pipeline of precision radiopharmaceutical therapies (RPTs) for cancer treatment, with a focus on actinium-based therapies utilizing the alpha-emitting isotope Ac225. These programs are described as potentially first-in-class and best-in-class drug development efforts targeting cancer.
Sources: RayzeBio official site
RayzeBio is a biopharmaceutical company that develops precision radiopharmaceutical therapies (RPTs) for cancer treatment. It specializes in actinium-based RPTs, using the alpha-emitting isotope Ac225 to target cancer cells. The company is now part of Bristol Myers Squibb.
Sources: RayzeBio official site
RayzeBio creates precision radiopharmaceutical therapies designed to treat cancer. It focuses on actinium-based RPTs, leveraging the alpha-emitting isotope Ac225, and maintains a pipeline of drug development programs aimed at delivering potentially first-in-class and best-in-class cancer treatments.
Sources: RayzeBio official site
RayzeBio can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: RayzeBio official site
RayzeBio is known for its innovation-leading position in actinium-based radiopharmaceutical therapies, particularly its use of the alpha-emitting isotope Ac225 in developing precision cancer treatments. It is also known for being acquired by and now operating as part of Bristol Myers Squibb.
Sources: RayzeBio official site
RayzeBio's radiopharmaceutical therapies and research are intended for cancer patients and are utilized by oncologists in treatment settings. Additionally, the broader healthcare and biopharmaceutical research community engages with RayzeBio's work in the pursuit of advanced radiopharmaceutical treatment options.
Sources: RayzeBio official site
RayzeBio scores 23/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
RayzeBio has a weak AI-visibility profile at 23/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (45/100) and its weakest is visibility (0/100). It benefits from a global traffic rank of #1,586,892 (Tranco), open access for AI crawlers (GPTBot, ClaudeBot, etc.) and machine-readable schema.org markup. The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, no strong Wikidata entry and a low Moz Domain Authority of 34/100. In a live check, Claude could already identify RayzeBio from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to RayzeBio: RANZCP (76/100), RANZCOG (76/100), The Royal Children's Hospital (76/100), Research Corporation Technologies (76/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.